Skip to main content
Erschienen in: Diabetologia 6/2005

01.06.2005 | Article

The influence of type 2 diabetes on fibrin structure and function

verfasst von: E. J. Dunn, R. A. S. Ariëns, P. J. Grant

Erschienen in: Diabetologia | Ausgabe 6/2005

Einloggen, um Zugang zu erhalten

Abstract

Aims/hypothesis

The precise mechanisms underlying the increased risk of cardiovascular disease (CVD) in type 2 diabetes are unclear. Fibrin clot structure has been related to CVD risk in the general population. We therefore assessed this in type 2 diabetic patients as a potential mechanism whereby diabetes influences CVD risk.

Methods

Fibrin clots were formed from fibrinogen purified from 150 subjects with type 2 diabetes and varying degrees of glycaemic control (assessed by HbA1c), and from 50 matched control subjects. Clot structure was assessed by turbidity, permeation and confocal microscopy. The specific effect of glucose itself was assessed by analysing the structure of clots formed from purified fibrinogen in the presence of increasing concentrations of the sugar.

Results

Clots formed by fibrinogen purified from type 2 diabetic subjects had a denser, less porous structure than those from control subjects. The structural changes found were related to the individual’s glycaemic control; HbA1c correlated negatively with permeation coefficient (K s) values (indicates clot pore size) (r=−0.57, p<0.0001) and positively with maximum absorbance (indicator of fibre size) (r=0.33, p<0.0001), branch point number (r=0.78, p<0.0001) and fibre density (r=0.63, p<0.0001). The ambient glucose level influenced clot structure; hypo- (<5 mmol) and hyperglycaemia (≥10 mmol/l) were both associated with a reduction in K s values and maximum absorbance, and with increased fibre density and branch point number within clots.

Conclusions/interpretation

The structural differences found to occur in type 2 diabetes and in association with hypo- and hyperglycaemia may confer increased resistance to fibrinolysis, and in consequence contribute to the increase in CVD risk in diabetic patients.
Literatur
1.
Zurück zum Zitat Kannel W, McGee D (2002) Diabetes and cardiovascular disease: the Framingham study. JAMA 241:2035–2038CrossRef Kannel W, McGee D (2002) Diabetes and cardiovascular disease: the Framingham study. JAMA 241:2035–2038CrossRef
2.
Zurück zum Zitat Kannel W, D’Agostino R, Wilson P, Belanger A, Gagnon D (1990) Diabetes, fibrinogen, and risk of cardiovascular disease: the Framingham experience. Am Heart J 120:672–676CrossRefPubMed Kannel W, D’Agostino R, Wilson P, Belanger A, Gagnon D (1990) Diabetes, fibrinogen, and risk of cardiovascular disease: the Framingham experience. Am Heart J 120:672–676CrossRefPubMed
3.
Zurück zum Zitat Reaven G (1988) Role of insulin resistance in human disease. Diabetes 37:1595–1607PubMed Reaven G (1988) Role of insulin resistance in human disease. Diabetes 37:1595–1607PubMed
6.
Zurück zum Zitat DeWood M, Spores J, Notske R et al (1980) Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med 303:897–902PubMed DeWood M, Spores J, Notske R et al (1980) Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med 303:897–902PubMed
7.
Zurück zum Zitat Zack P, Ischinger T, Aker U, Dincer B, Kennedy H (1984) The occurrence of angiographically detected intracoronary thrombus in patients with unstable angina pectoris. Am Heart J 108:1408–1412CrossRefPubMed Zack P, Ischinger T, Aker U, Dincer B, Kennedy H (1984) The occurrence of angiographically detected intracoronary thrombus in patients with unstable angina pectoris. Am Heart J 108:1408–1412CrossRefPubMed
8.
Zurück zum Zitat Smith E, Alexander K, Massie I (1976) Insoluble ‘fibrin’ in human aortic intima. Quantitative studies on the relationship between insoluble ‘fibrin’, soluble fibrinogen and low density lipoprotein. Atherosclerosis 23:19–39PubMed Smith E, Alexander K, Massie I (1976) Insoluble ‘fibrin’ in human aortic intima. Quantitative studies on the relationship between insoluble ‘fibrin’, soluble fibrinogen and low density lipoprotein. Atherosclerosis 23:19–39PubMed
9.
Zurück zum Zitat Bini A, Fenoglio J, Mesa-Tejada R, Kudryk B, Kaplan K (1989) Identification and distribution of fibrinogen, fibrin, and fibrin(ogen) degradation products in atherosclerosis. Arteriosclerosis 9:109–121PubMed Bini A, Fenoglio J, Mesa-Tejada R, Kudryk B, Kaplan K (1989) Identification and distribution of fibrinogen, fibrin, and fibrin(ogen) degradation products in atherosclerosis. Arteriosclerosis 9:109–121PubMed
10.
Zurück zum Zitat Kadish J (1979) Fibrin and atherogenesis—a hypothesis. Atherosclerosis 33:409–413PubMed Kadish J (1979) Fibrin and atherogenesis—a hypothesis. Atherosclerosis 33:409–413PubMed
11.
Zurück zum Zitat Bini A, Fenoglio J, Sobel J, Owen J, Fejgl M, Kaplan K (1987) Immunohistochemical characterization of fibrinogen, fibrin I, and fibrin II in human thrombi and atherosclerotic lesions. Blood 69:1038–1045PubMed Bini A, Fenoglio J, Sobel J, Owen J, Fejgl M, Kaplan K (1987) Immunohistochemical characterization of fibrinogen, fibrin I, and fibrin II in human thrombi and atherosclerotic lesions. Blood 69:1038–1045PubMed
12.
Zurück zum Zitat Thompson W, Smith E (1989) Atherosclerosis and the coagulation system. J Pathol 159:97–106PubMed Thompson W, Smith E (1989) Atherosclerosis and the coagulation system. J Pathol 159:97–106PubMed
13.
Zurück zum Zitat Ernst E, Resch K (1993) Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature. Ann Intern Med 118:956–963PubMed Ernst E, Resch K (1993) Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature. Ann Intern Med 118:956–963PubMed
14.
Zurück zum Zitat Dunn E, Ariens R, de Lange M et al (2004) Genetics of fibrin clot structure: a twin study. Blood 103:1735–1740CrossRefPubMed Dunn E, Ariens R, de Lange M et al (2004) Genetics of fibrin clot structure: a twin study. Blood 103:1735–1740CrossRefPubMed
15.
Zurück zum Zitat Fatah K, Silveira A, Tornvall P, Karpe F, Blomback M, Hamsten A (1996) Proneness to formation of tight and rigid fibrin gel structures in men with myocardial infarction at a young age. Thromb Haemost 76:535–540PubMed Fatah K, Silveira A, Tornvall P, Karpe F, Blomback M, Hamsten A (1996) Proneness to formation of tight and rigid fibrin gel structures in men with myocardial infarction at a young age. Thromb Haemost 76:535–540PubMed
16.
Zurück zum Zitat Collet J, Park D, Lesty C et al (2000) Influence of fibrin network conformation and fibrin fibre diameter on fibrinolysis speed: dynamic and structural analysis approaches by confocal microscopy. Arterioscler Thromb Vasc Biol 20:1354–1361PubMed Collet J, Park D, Lesty C et al (2000) Influence of fibrin network conformation and fibrin fibre diameter on fibrinolysis speed: dynamic and structural analysis approaches by confocal microscopy. Arterioscler Thromb Vasc Biol 20:1354–1361PubMed
17.
Zurück zum Zitat Jorneskog G, Egberg N, Fagrell B et al (1996) Altered properties of the fibrin gel structure in patients with IDDM. Diabetologia 39:1519–1523CrossRefPubMed Jorneskog G, Egberg N, Fagrell B et al (1996) Altered properties of the fibrin gel structure in patients with IDDM. Diabetologia 39:1519–1523CrossRefPubMed
18.
Zurück zum Zitat Nair C, Azhar A, Wilson J, Dhall D (1991) Studies of fibrin network structure in human plasma, part II—clinical application: diabetes and anti-diabetic drugs. Thromb Res 64:477–485CrossRefPubMed Nair C, Azhar A, Wilson J, Dhall D (1991) Studies of fibrin network structure in human plasma, part II—clinical application: diabetes and anti-diabetic drugs. Thromb Res 64:477–485CrossRefPubMed
19.
Zurück zum Zitat Gabriel D, Muga K, Boothroyd E (1992) The effect of fibrin structure on fibrinolysis. J Biol Chem 267:24259–24263PubMed Gabriel D, Muga K, Boothroyd E (1992) The effect of fibrin structure on fibrinolysis. J Biol Chem 267:24259–24263PubMed
20.
Zurück zum Zitat Lutjens A, te Velde A, v.d. Veen E, v.d. Meer J (1985) Glycosylation of human fibrinogen in vivo. Diabetologia 28:87–89PubMed Lutjens A, te Velde A, v.d. Veen E, v.d. Meer J (1985) Glycosylation of human fibrinogen in vivo. Diabetologia 28:87–89PubMed
21.
Zurück zum Zitat Brownlee M, Vlassara H, Cerami A (1983) Nonenzymatic glycosylation reduces the susceptibility of fibrin to degradation by plasmin. Diabetes 32:680–684PubMed Brownlee M, Vlassara H, Cerami A (1983) Nonenzymatic glycosylation reduces the susceptibility of fibrin to degradation by plasmin. Diabetes 32:680–684PubMed
22.
Zurück zum Zitat Ney K, Pasqua J, Colley K, Guthrow C, Pizzo S (1985) In vitro preparation of nonenzymatically glycosylated human transferrin, alpha2-macroglobulin, and fibrinogen with preservation of function. Diabetes 34:462–470PubMed Ney K, Pasqua J, Colley K, Guthrow C, Pizzo S (1985) In vitro preparation of nonenzymatically glycosylated human transferrin, alpha2-macroglobulin, and fibrinogen with preservation of function. Diabetes 34:462–470PubMed
23.
Zurück zum Zitat Bobbink I, Tekelenburg W, Sixma J, de Boer H, Banga J, de Groot P (1997) Glycated proteins modulate tissue-plasminogen activator-catalyzed plasminogen activation. Biochem Biophys Res Commun 240:595–601CrossRefPubMed Bobbink I, Tekelenburg W, Sixma J, de Boer H, Banga J, de Groot P (1997) Glycated proteins modulate tissue-plasminogen activator-catalyzed plasminogen activation. Biochem Biophys Res Commun 240:595–601CrossRefPubMed
24.
Zurück zum Zitat Takebe M, Soe G, Kohno I, Sugo T, Matsuda M (1995) Calcium ion-dependent monoclonal antibody against human fibrinogen: preparation, characterization, and application to fibrinogen purification. Thromb Haemost 73:662–667PubMed Takebe M, Soe G, Kohno I, Sugo T, Matsuda M (1995) Calcium ion-dependent monoclonal antibody against human fibrinogen: preparation, characterization, and application to fibrinogen purification. Thromb Haemost 73:662–667PubMed
25.
Zurück zum Zitat Ariens R, Philippou H, Nagaswami C, Weisel J, Lane D, Grant PJ (2000) The factor XIII V34L polymorphism accelerates thrombin activation of factor XIII and affects cross-linked fibrin structure. Blood 96:988–995PubMed Ariens R, Philippou H, Nagaswami C, Weisel J, Lane D, Grant PJ (2000) The factor XIII V34L polymorphism accelerates thrombin activation of factor XIII and affects cross-linked fibrin structure. Blood 96:988–995PubMed
26.
Zurück zum Zitat Mills J, Ariens R, Mansfield M, Grant PJ (2002) Altered fibrin clot structure in healthy relatives of patients with premature coronary artery disease. Circulation 106:1938–1942CrossRefPubMed Mills J, Ariens R, Mansfield M, Grant PJ (2002) Altered fibrin clot structure in healthy relatives of patients with premature coronary artery disease. Circulation 106:1938–1942CrossRefPubMed
27.
Zurück zum Zitat Weisel J, Nagaswami C (1992) Computer modelling of fibrin polymerization kinetics correlated with electron microscope and turbidity observations: clot structure and assembly are kinetically controlled. Biophys J 63:111–128PubMed Weisel J, Nagaswami C (1992) Computer modelling of fibrin polymerization kinetics correlated with electron microscope and turbidity observations: clot structure and assembly are kinetically controlled. Biophys J 63:111–128PubMed
28.
Zurück zum Zitat Standeven K, Ariens R, Whitaker P, Ashcroft A, Weisel J, Grant PJ (2002) The effect of dimethylbiguanide on thrombin activity, FXIII activation, fibrin polymerization, and fibrin clot formation. Diabetes 51:189–197PubMed Standeven K, Ariens R, Whitaker P, Ashcroft A, Weisel J, Grant PJ (2002) The effect of dimethylbiguanide on thrombin activity, FXIII activation, fibrin polymerization, and fibrin clot formation. Diabetes 51:189–197PubMed
29.
Zurück zum Zitat Janus T, Lewis S, Lorand L, Shafer J (1983) Promotion of thrombin-catalyzed activation of factor XIII by fibrinogen. Biochemistry 22:6269–6272CrossRefPubMed Janus T, Lewis S, Lorand L, Shafer J (1983) Promotion of thrombin-catalyzed activation of factor XIII by fibrinogen. Biochemistry 22:6269–6272CrossRefPubMed
30.
Zurück zum Zitat Wilf J, Gladner J, Minton A (1985) Acceleration of fibrin gel formation by unrelated proteins. Thromb Res 37:681–688CrossRefPubMed Wilf J, Gladner J, Minton A (1985) Acceleration of fibrin gel formation by unrelated proteins. Thromb Res 37:681–688CrossRefPubMed
31.
Zurück zum Zitat Torbet J (1986) Fibrin assembly in human plasma and fibrinogen/albumin mixtures. Biochemistry 25:5309–5314CrossRefPubMed Torbet J (1986) Fibrin assembly in human plasma and fibrinogen/albumin mixtures. Biochemistry 25:5309–5314CrossRefPubMed
32.
Zurück zum Zitat Doolittle R (1984) Fibrinogen and fibrin. Annu Rev Biochem 53:195–229PubMed Doolittle R (1984) Fibrinogen and fibrin. Annu Rev Biochem 53:195–229PubMed
33.
Zurück zum Zitat Weisel J (1986) Fibrin assembly: lateral aggregation and the role of the two pairs of fibrinopeptides. Biophys J 50:1079–1083PubMed Weisel J (1986) Fibrin assembly: lateral aggregation and the role of the two pairs of fibrinopeptides. Biophys J 50:1079–1083PubMed
34.
Zurück zum Zitat Muszbek L, Adany R, Mikkola H (1996) Novel aspects of blood coagulation factor XIII: I. Structure, distribution, activation, and function. Crit Rev Clin Lab Sci 33:357–421PubMed Muszbek L, Adany R, Mikkola H (1996) Novel aspects of blood coagulation factor XIII: I. Structure, distribution, activation, and function. Crit Rev Clin Lab Sci 33:357–421PubMed
35.
Zurück zum Zitat McVerry B, Thorpe S, Joe F, Gaffney P, Huehns E (1981) Non-enzymatic glycation of fibrinogen. Haemostasis 10:261–270PubMed McVerry B, Thorpe S, Joe F, Gaffney P, Huehns E (1981) Non-enzymatic glycation of fibrinogen. Haemostasis 10:261–270PubMed
36.
Zurück zum Zitat Lorand L (2001) Factor XIII: structure, activation, and interactions with fibrinogen and fibrin. Ann NY Acad Sci 936:291–311PubMed Lorand L (2001) Factor XIII: structure, activation, and interactions with fibrinogen and fibrin. Ann NY Acad Sci 936:291–311PubMed
37.
Zurück zum Zitat Weisel J, Veklich Y, Gorkun O (1993) The sequence of cleavage of fibrinopeptides from fibrinogen is important for protofibril formation and enhancement of lateral aggregation in fibrin clots. J Mol Biol 232:285–297CrossRefPubMed Weisel J, Veklich Y, Gorkun O (1993) The sequence of cleavage of fibrinopeptides from fibrinogen is important for protofibril formation and enhancement of lateral aggregation in fibrin clots. J Mol Biol 232:285–297CrossRefPubMed
38.
Zurück zum Zitat Weisel J, Medved L (2001) The structure and function of the alpha-C domains of fibrinogen. Ann NY Acad Sci 936:312–327PubMed Weisel J, Medved L (2001) The structure and function of the alpha-C domains of fibrinogen. Ann NY Acad Sci 936:312–327PubMed
39.
Zurück zum Zitat Juhan-Vague I, Roul C, Alessi M, Ardissone J, Heim M, Vague P (1989) Increased plasminogen activator inhibitor activity in non insulin dependent diabetic patients. Relationship with plasma insulin. Thromb Haemost 61:370–373 Juhan-Vague I, Roul C, Alessi M, Ardissone J, Heim M, Vague P (1989) Increased plasminogen activator inhibitor activity in non insulin dependent diabetic patients. Relationship with plasma insulin. Thromb Haemost 61:370–373
40.
Zurück zum Zitat Zairis M, Lyras A, Makrygiannis S et al (2004) Type 2 diabetes and intravenous thrombolysis outcome in the setting of ST elevation myocardial infarction. Diabetes Care 27:967–971PubMed Zairis M, Lyras A, Makrygiannis S et al (2004) Type 2 diabetes and intravenous thrombolysis outcome in the setting of ST elevation myocardial infarction. Diabetes Care 27:967–971PubMed
41.
Zurück zum Zitat Rand R (2004) Probing the role of water in protein conformation and function. Philos Trans R Soc Lond B Biol Sci 359:1277–1285CrossRefPubMed Rand R (2004) Probing the role of water in protein conformation and function. Philos Trans R Soc Lond B Biol Sci 359:1277–1285CrossRefPubMed
42.
Zurück zum Zitat Capes S, Hunt D, Malmberg K, Gerstein H (2000) Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview. Lancet 355:773–778CrossRefPubMed Capes S, Hunt D, Malmberg K, Gerstein H (2000) Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview. Lancet 355:773–778CrossRefPubMed
43.
Zurück zum Zitat Wei M, Gibbons L, Mitchell T, Kampert J, Stern M, Blair S (2000) Low fasting plasma glucose level as a predictor of cardiovascular disease and all-cause mortality. Circulation 101:2047–2052PubMed Wei M, Gibbons L, Mitchell T, Kampert J, Stern M, Blair S (2000) Low fasting plasma glucose level as a predictor of cardiovascular disease and all-cause mortality. Circulation 101:2047–2052PubMed
44.
Zurück zum Zitat Galanakis D (1992) Anticoagulant albumin fragments that bind to fibrinogen/fibrin: possible implications. Semin Thromb Hemost 18:44–52PubMed Galanakis D (1992) Anticoagulant albumin fragments that bind to fibrinogen/fibrin: possible implications. Semin Thromb Hemost 18:44–52PubMed
45.
Zurück zum Zitat Baynes J, Thorpe S (1999) Role of oxidative stress in diabetic complications. A new perspective on an old paradigm. Diabetes 48:1–9PubMed Baynes J, Thorpe S (1999) Role of oxidative stress in diabetic complications. A new perspective on an old paradigm. Diabetes 48:1–9PubMed
46.
Zurück zum Zitat Shacter E, Williams J, Levine R (1995) Oxidative modification of fibrinogen inhibits thrombin catalyzed clot formation. Free Radic Biol Med 18:815–821CrossRefPubMed Shacter E, Williams J, Levine R (1995) Oxidative modification of fibrinogen inhibits thrombin catalyzed clot formation. Free Radic Biol Med 18:815–821CrossRefPubMed
Metadaten
Titel
The influence of type 2 diabetes on fibrin structure and function
verfasst von
E. J. Dunn
R. A. S. Ariëns
P. J. Grant
Publikationsdatum
01.06.2005
Erschienen in
Diabetologia / Ausgabe 6/2005
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-005-1742-2

Weitere Artikel der Ausgabe 6/2005

Diabetologia 6/2005 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.